These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

358 related items for PubMed ID: 27742657

  • 1. Chromoplectic TPM3-ALK rearrangement in a patient with inflammatory myofibroblastic tumor who responded to ceritinib after progression on crizotinib.
    Mansfield AS, Murphy SJ, Harris FR, Robinson SI, Marks RS, Johnson SH, Smadbeck JB, Halling GC, Yi ES, Wigle D, Vasmatzis G, Jen J.
    Ann Oncol; 2016 Nov; 27(11):2111-2117. PubMed ID: 27742657
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusions.
    Lovly CM, Gupta A, Lipson D, Otto G, Brennan T, Chung CT, Borinstein SC, Ross JS, Stephens PJ, Miller VA, Coffin CM.
    Cancer Discov; 2014 Aug; 4(8):889-95. PubMed ID: 24875859
    [Abstract] [Full Text] [Related]

  • 4. Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers.
    Facchinetti F, Loriot Y, Kuo MS, Mahjoubi L, Lacroix L, Planchard D, Besse B, Farace F, Auger N, Remon J, Scoazec JY, André F, Soria JC, Friboulet L.
    Clin Cancer Res; 2016 Dec 15; 22(24):5983-5991. PubMed ID: 27401242
    [Abstract] [Full Text] [Related]

  • 5. Durable brain response with pulse-dose crizotinib and ceritinib in ALK-positive non-small cell lung cancer compared with brain radiotherapy.
    Dudnik E, Siegal T, Zach L, Allen AM, Flex D, Yust-Katz S, Limon D, Hirsch FR, Peled N.
    J Clin Neurosci; 2016 Apr 15; 26():46-9. PubMed ID: 26677785
    [Abstract] [Full Text] [Related]

  • 6. Partial Response to Ceritinib in a Patient With Abdominal Inflammatory Myofibroblastic Tumor Carrying a TFG-ROS1 Fusion.
    Li Y, Chen X, Qu Y, Fan JM, Li Y, Peng H, Zheng Y, Zhang Y, Zhang HB.
    J Natl Compr Canc Netw; 2019 Dec 15; 17(12):1459-1462. PubMed ID: 31805529
    [Abstract] [Full Text] [Related]

  • 7. Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial.
    Shaw AT, Kim TM, Crinò L, Gridelli C, Kiura K, Liu G, Novello S, Bearz A, Gautschi O, Mok T, Nishio M, Scagliotti G, Spigel DR, Deudon S, Zheng C, Pantano S, Urban P, Massacesi C, Viraswami-Appanna K, Felip E.
    Lancet Oncol; 2017 Jul 15; 18(7):874-886. PubMed ID: 28602779
    [Abstract] [Full Text] [Related]

  • 8. Molecular characterization of inflammatory myofibroblastic tumors with frequent ALK and ROS1 gene fusions and rare novel RET rearrangement.
    Antonescu CR, Suurmeijer AJ, Zhang L, Sung YS, Jungbluth AA, Travis WD, Al-Ahmadie H, Fletcher CD, Alaggio R.
    Am J Surg Pathol; 2015 Jul 15; 39(7):957-67. PubMed ID: 25723109
    [Abstract] [Full Text] [Related]

  • 9. Metastatic Anaplastic Lymphoma Kinase-1 (ALK-1)-Rearranged Inflammatory Myofibroblastic Sarcoma to the Brain with Leptomeningeal Involvement: Favorable Response to Serial ALK Inhibitors: A Case Report.
    Yuan C, Ma MJ, Parker JV, Mekhail TM.
    Am J Case Rep; 2017 Jul 17; 18():799-804. PubMed ID: 28713152
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children's Oncology Group Study.
    Mossé YP, Voss SD, Lim MS, Rolland D, Minard CG, Fox E, Adamson P, Wilner K, Blaney SM, Weigel BJ.
    J Clin Oncol; 2017 Oct 01; 35(28):3215-3221. PubMed ID: 28787259
    [Abstract] [Full Text] [Related]

  • 12. Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial.
    Kim DW, Mehra R, Tan DSW, Felip E, Chow LQM, Camidge DR, Vansteenkiste J, Sharma S, De Pas T, Riely GJ, Solomon BJ, Wolf J, Thomas M, Schuler M, Liu G, Santoro A, Sutradhar S, Li S, Szczudlo T, Yovine A, Shaw AT.
    Lancet Oncol; 2016 Apr 01; 17(4):452-463. PubMed ID: 26973324
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Targeted therapies in non-small cell lung cancer: a focus on ALK/ROS1 tyrosine kinase inhibitors.
    Sgambato A, Casaluce F, Maione P, Gridelli C.
    Expert Rev Anticancer Ther; 2018 Jan 01; 18(1):71-80. PubMed ID: 29187012
    [Abstract] [Full Text] [Related]

  • 16. Role of anaplastic lymphoma kinase inhibition in the treatment of non-small-cell lung cancer.
    Croegaert K, Kolesar JM.
    Am J Health Syst Pharm; 2015 Sep 01; 72(17):1456-62. PubMed ID: 26294238
    [Abstract] [Full Text] [Related]

  • 17. A case report of epithelioid inflammatory myofibroblastic sarcoma with RANBP2-ALK fusion gene treated with the ALK inhibitor, crizotinib.
    Kimbara S, Takeda K, Fukushima H, Inoue T, Okada H, Shibata Y, Katsushima U, Tsuya A, Tokunaga S, Daga H, Okuno T, Inoue T.
    Jpn J Clin Oncol; 2014 Sep 01; 44(9):868-71. PubMed ID: 25028698
    [Abstract] [Full Text] [Related]

  • 18. Post-crizotinib management of effective ceritinib therapy in a patient with ALK-positive non-small cell lung cancer.
    Won B, Mambetsariev I, Salgia R.
    BMC Cancer; 2016 Aug 02; 16():568. PubMed ID: 27480287
    [Abstract] [Full Text] [Related]

  • 19. TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumors.
    Lawrence B, Perez-Atayde A, Hibbard MK, Rubin BP, Dal Cin P, Pinkus JL, Pinkus GS, Xiao S, Yi ES, Fletcher CD, Fletcher JA.
    Am J Pathol; 2000 Aug 02; 157(2):377-84. PubMed ID: 10934142
    [Abstract] [Full Text] [Related]

  • 20. ALK inhibitors in the treatment of advanced NSCLC.
    Gridelli C, Peters S, Sgambato A, Casaluce F, Adjei AA, Ciardiello F.
    Cancer Treat Rev; 2014 Mar 02; 40(2):300-6. PubMed ID: 23931927
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.